10-Q: Avenue Therapeutics Reports Q1 2025 Results, Navigates Nasdaq Delisting and Strategic Shifts

Avenue Therapeutics reported its Q1 2025 financial results, detailing a net loss reduction, Nasdaq delisting, and the termination of the AnnJi License Agreement.

Summary

• Avenue Therapeutics, Inc. reported a net loss of $1.9 million for the three months ended March 31, 2025, compared to a net loss of $4.3 million for the same period in 2024.
• The company's common stock was delisted from Nasdaq on March 19, 2025, and is now trading on the over-the-counter market under the symbol ATXI.
• Avenue terminated its license agreement with AnnJi Pharmaceutical Co. Ltd. for AJ201, a clinical product candidate for the treatment of spinal and bulbar muscular atrophy (SBMA).
• The company will receive $2.0 million from AnnJi in connection with the termination, as well as potential milestone and royalty payments.
• Research and development expenses decreased to $0.4 million from $2.4 million year-over-year, primarily due to the termination of the AJ201 program.
• General and administrative expenses increased to $1.5 million from $1.3 million year-over-year, mainly due to higher legal expenses.
• As of March 31, 2025, Avenue Therapeutics had $3.5 million in cash and cash equivalents.
• The company states that it needs additional funding to continue operations and develop its product candidates.
• There is substantial doubt about the company's ability to continue as a going concern within one year from the date of the report.

Sentiment

Score: 3

Explanation: The sentiment is low due to the Nasdaq delisting, the going concern warning, and the need for additional funding, despite the reduced net loss.

Positives

• The net loss decreased significantly compared to the same period last year, from $4.3 million to $1.9 million.
• The termination of the AnnJi License Agreement resulted in Avenue receiving $2.0 million in payments.
• Research and development expenses decreased, reflecting a strategic shift in focus.
• The company is exploring strategic alternatives for Baergic and/or BAER-101, which may unlock value.

Negatives

• The company's common stock was delisted from Nasdaq, which could reduce liquidity and investor interest.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company needs additional funding to continue operations and develop its product candidates.
• General and administrative expenses increased due to higher legal expenses.
• The termination of the AnnJi License Agreement means the company will no longer be developing AJ201.

Risks

• The company's dependence on securing additional funding to continue operations poses a significant risk.
• The delisting from Nasdaq could negatively impact the company's stock price and ability to raise capital.
• The company's product candidates may not receive regulatory approval or be successfully commercialized.
• The company faces competition from other pharmaceutical companies.
• The company relies on third parties for various aspects of its operations, which could lead to delays or other issues.
• The company's common stock may be considered a 'penny stock' and, therefore, may be subject to certain rules that make it difficult for brokers, dealers, or investors to sell the shares.

Future Outlook

The company expects to continue incurring substantial losses from operations for the foreseeable future and will require additional financing to carry out its business plan and implement its strategy. There is no assurance that the company will be able to raise the necessary capital under acceptable terms, if at all.

Management Comments

• Management states that the company needs additional funding to continue operations and develop its product candidates.
• Management acknowledges substantial doubt about the company's ability to continue as a going concern.

Industry Context

Avenue Therapeutics' situation reflects the challenges faced by small pharmaceutical companies in funding drug development and navigating regulatory hurdles. The delisting from Nasdaq and the need for additional capital are common issues in the biotech industry, particularly for companies without revenue-generating products. The termination of the AnnJi agreement and the focus on IV tramadol and BAER-101 suggest a strategic shift towards core assets.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in securing funding and achieving regulatory approval.
• The decrease in R&D spending following the termination of a program is a common occurrence in the industry.
• The need for additional capital is typical for companies in the clinical development stage.
• Companies like BioCryst Pharmaceuticals and Madrigal Pharmaceuticals have successfully navigated similar challenges by securing partnerships and achieving regulatory milestones.
• Avenue's situation is comparable to that of companies like Adamis Pharmaceuticals, which have faced delisting and financial difficulties.

Related Party Transactions

• The company recorded expense related to the Management Services Agreement (MSA) with Fortress of $0.1 million for both the three months ended March 31, 2025 and 2024.
• The company issued 23,474 shares of common stock to Fortress related to the Financing Equity Fee for the three months ended March 31, 2025.
• The Annual Stock Dividend payable to the Company is 2.5% of common stock calculated as a percentage of fully diluted outstanding capital and became effective as of November 8, 2022.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of further stock price decline.
• Employees face uncertainty due to the company's financial instability and potential for layoffs.
• Customers may be affected by delays in the development and commercialization of the company's product candidates.
• Suppliers and creditors face the risk of non-payment if the company is unable to secure additional funding.
• The termination of the AnnJi License Agreement may impact patients who could have benefited from AJ201.

Next Steps

• The company will seek additional funding through debt or equity offerings or other arrangements.
• The company will continue to develop and attempt to gain regulatory approval for IV tramadol and BAER-101.
• The company will explore strategic alternatives for Baergic and/or BAER-101.
• The company plans to continue to file its required periodic reports and other filings with the SEC.

Key Dates

Keywords

Avenue Therapeutics, financial results, delisting, AnnJi, AJ201, IV tramadol, BAER-101, pharmaceutical, neurologic diseases, OTC market